Foresite Capital is building a portfolio to create enduring investor returns. Our current portfolio includes transformative, category-defining companies across the therapeutic, diagnostic, device and services sectors.
Aerie Pharmaceuticals, Inc.
Allergen Research Corporation (ARC)
Intarcia Therapeutics, Inc.
Karyopharm Therapeutics, Inc.
Orexigen Therapeutics, Inc.
Sotera Wireless, Inc.
Tarsa Therapeutics, Inc.
Universal American Corporation
10X Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing short read sequencers. The Company does this through a combination of elegant microfluidics, chemistry and bioinformatics. With the GemCode Platform, researchers can now find structural variants, haplotypes, and other valuable long range information while leveraging existing sequencing workflows.Back to Top
Aduro BioTech is a development-stage biopharmaceutical company engaged in the development of early-stage cancer therapies. Aduro currently has three products in human trials.Back to Top
Aerie (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Glaucoma is one of the largest segments in the global ophthalmic market. In 2013, branded and generic glaucoma product sales exceeded $4.5 billion in the United States, Europe and Japan in aggregate, according to IMS. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness.Back to Top
Alder’s mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles:
As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.
As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.Back to Top
ARC is developing desensitization treatments for food allergies. In our lead clinical program, for peanut allergy, patients ingest gradually increasing amounts of our standardized, pharmaceutical-grade peanut protein formulation in a controlled regimen called CODIT™ (characterized oral desensitization immunotherapy), our proprietary approach to oral immunotherapy.Back to Top
Auspex Pharmaceuticals (Nasdaq: ASPX) is a biopharmaceutical company focused on the development and commercialization of novel medicines for people with movement disorders and other rare diseases, including orphan diseases, which are rare diseases that affect fewer than 200,000 people in the United States. Our pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, and tardive dyskinesia and Tourette syndrome, subsets of either of which may be deemed to be orphan diseases, as well as other orphan indications.Back to Top
BioDelivery Sciences (Nasdaq: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The company is utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
BDSI's development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows them to potentially obtain more timely and efficient approval of new formulations of previously approved therapeuticsBack to Top
Ignyta, Inc. is a biotechnology company catalyzing personalized medicine in cancer. Ignyta is pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection.Back to Top
Intarcia Therapeutics, Inc., has developed a revolutionary device that could become a major treatment option for Type II diabetes. The device, ITCA 650, is a matchstick-sized osmotic pump that delivers GLP-1 (Glucagon-Like Peptide-1), an important therapy for diabetes, in a manner that avoids the need for regular, painful injections while producing efficacy and tolerability results that are potentially preferable to existing therapies.Back to Top
Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.Back to Top
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's scientific expertise is focused on the understanding of the regulation of intracellular transport between the nucleus and the cytoplasm. Karyopharm has discovered and developed novel, small molecule, Selective Inhibitors of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. In addition to cancer, Karyopharm believe's that their SINE compounds have the potential to provide therapeutic benefit in a number of additional indications, including autoimmune and inflammatory diseases, wound healing, HIV and influenza.Back to Top
Orexigen Therapeutics, Inc. (Nasdaq: OREX) is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB-32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB-32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB-32 in the United States. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials.Back to Top
Scynexis, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners.Back to Top
Sequenta, Inc. has developed a transformative diagnostic technology that could become the new standard in initial and follow up testing for patients suffering from various forms of leukemia and lymphoma. Using just a small vial of blood, Sequenta’s test, called ClonoSight, is able to determine the specific genetic sequence that uniquely identifies the leukemia or lymphoma cells that a patient has and uses that DNA fingerprint to track cancer cells circulating in the patient’s blood. By analyzing samples before, during and after treatment, this test can determine a patient’s initial response to treatment and monitor over time for “minimal residual disease” (MRD) and possible cancer relapse.Back to Top
Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.Back to Top
Tarsa Therapeutics, Inc. has developed an oral formulation of calcitonin, a recombinant peptide hormone that inhibits bone resorption, a key process underlying the development of post-menopausal osteoporosis.Back to Top
Universal American Corporation (NYSE: UAM) is an insurance, Finance and administrative services company that specializes in offering products to the senior and self-employed markets. UA Corp has targeted the senior market in particular because it is the fastest growing demographic segment in the country. UAC contracts with the federal government to offer Medicare Advantages with Prescription Drug Plans. Universal American is currently the 3rd largest Medicare Prescription Drug Plan organization and the Fifth largest Medicare Advantage Private-Fee-for-Service organization in the U.S.Back to Top
Xencor, Inc. provides protein engineering technology platforms in the biotechnology industry.
Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.Back to Top
Zafgen, Inc. is the world's first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories for later use. The balance between how the body stores excess calories and later accesses these depots when required plays a critical role in determining the overall size of the fat tissue, and therefore, an individual's weight. Zafgen's groundbreaking approach targets obesity at its biological foundation by safely restoring the balance of fat metabolism, driving the loss of fat and a return to a more healthy body weight. Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry.Back to Top